NASDAQ · QNCX
Healthcare · Biotechnology
$31.73
Up+$2.37 (+8.07%)
Updated Oct 28, 2026, 2:15 AM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · QNCX
1M range · 9 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
QNCX closed at $31.73 after 9 trading sessions, up 1.80% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $30.50 | $37.00 | $29.8396 | $31.73 | 138.74K |
| Oct 8, 2026 | $27.095 | $29.80 | $26.65 | $29.36 | 31.88K |
| Oct 7, 2026 | $26.74 | $27.95 | $26.72 | $26.72 | 12.7K |
| Oct 6, 2026 | $27.68 | $28.15 | $26.81 | $26.81 | 27.83K |
| Oct 5, 2026 | $29.00 | $29.78 | $28.00 | $28.10 | 22.1K |
| Oct 2, 2026 | $30.20 | $31.06 | $29.20 | $29.20 | 68.38K |
| Oct 1, 2026 | $31.99 | $31.99 | $29.20 | $30.68 | 20.92K |
| Sep 30, 2026 | $31.97 | $32.5923 | $30.62 | $31.01 | 10.68K |
| Sep 29, 2026 | $28.70 | $32.00 | $26.45 | $31.17 | 21.8K |
The latest Smart Investors Daily articles mentioning QNCX.
Company
Market Activity
Research & News
QNCX research
Company profile and research snapshot.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 9, 2026 | Raymond James | Outperform | — |
| Sep 24, 2026 | Rodman & Renshaw | Buy | — |
| Sep 22, 2026 | Citizens | Market Outperform | — |
| Aug 18, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 29, 2026 | Oppenheimer | Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 9, 2026
Quince Therapeutics (NASDAQ:QNCX) has changed its name to IRulya Therapeutics Inc. , effective October 9, 2026, as the biotechnology company shifts its focus towards developing an inhaled treatment for several serious lung diseases.
Yahoo · Oct 9, 2026
Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO Keith R. Fandrick, Ph.D. Board strengthened with the addition of Catherine Bonuccelli, M.D., Leone Patterson, James Valentine, J.D., M.H.S., and Drayton Wise Cash balance of $116 million as of June 30, 2026 expected to fund operations through the end of 2028, supporting anticipated clinical data readou
Benzinga · Oct 9, 2026
Raymond James analyst Tiago Fauth initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Outperform rating and announces Price Target of $72.
SeekingAlpha · Oct 6, 2026
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call October 6, 2026 11:00 AM EDTCompany ParticipantsDirk Thye - CEO, Chief Medical Officer &...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning QNCX.
